Xenon Pharmaceuticals Inc.
XENE
Positions held
Your positionsXENE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Xenon Pharmaceuticals is positioned in the biotechnology sector, which is known for its potential for high returns due to innovation and unmet medical needs.
- Xenon has a strong current ratio of 21.015, indicating excellent liquidity and the ability to cover short-term obligations.
- The company's market cap stands at approximately $3.54 billion, reflecting significant investor interest and potential for growth.
- Xenon Pharmaceuticals has not generated any revenue in recent quarters, raising concerns about its business viability.
- The company reported a net income of -110.736 million in Q2 2026, continuing a trend of negative earnings over multiple quarters.
- Xenon's recommendation score is a 'strong buy', but its overall score is -6.00, indicating a bearish trend with multiple negative indicators.
Fundamentals
| Market cap | $3.50B | Enterprise value | $2.58B | Trailing P/E | — | Forward P/E | -7.67 |
| PEG | — | Price / book | 2.82 | Beta | 0.60 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -43.6% | ROA | -28.0% | Debt / equity | 0.01 |
| Current ratio | 21.02 | Free cash flow | -$203.55M | Analyst recommendation | strong_buy | Mean target | $73.37 |
| 52w high | $72.66 | 52w low | $35.06 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$111M | -$102M | -$105M | -$90.9M | -$84.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$123M | -$112M | -$110M | -$96.3M | -$94.2M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.5M | $0.0M | $0.0M | $9.4M | — |
| Op margin | -4974.3% | — | — | -1368.9% | — |
| Net income | -$346M | -$234M | -$182M | -$125M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$373M | -$279M | -$214M | -$129M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Insiders Are Buying These 2 ‘Strong Buy’ Stocks With Over 60% Upside
2026-10-02 · Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 · Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month
2026-10-01 · Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says
2026-10-01 · Xenon Pharmaceuticals Insider Bought Shares Worth $1,121,400, According to a Recent SEC Filing
2026-09-29 · Ian Mortimer Receives the 2026 Bloom Burton Award
2026-09-29 · Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
2026-09-27 · Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
2026-09-23 · Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?
2026-09-22 · Xenon stock lost 30%, but the FDA story is more complicated
2026-09-21 · Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
2026-09-21 · Company News for Sep 21, 2026
Price (daily)
Full chart · RSI · MACD · patterns